ISSN: 1859 - 2872
Factors associated with liver fibrosis according to NAFLD, MAFLD, and MASLD criteria in individuals over 55 years old with fatty liver disease
Main Article Content
Keywords
Abstract
Objective: To determine the prevalence and associated factors of liver fibrosis in individuals over 55 years of age with hepatic steatosis, defined according to the NAFLD, MAFLD, and MASLD criteria. Subject and method: A cross-sectional study was conducted on 397 patients aged ≥55 years attending Dai Phuoc General Clinic, Ho Chi Minh City, from October 15 to December 2024. Result: The NAFLD, MAFLD, and MASLD groups were comparable in terms of age, BMI, waist circumference, and biochemical parameters. However, the MAFLD group had a higher proportion of males (58.7%) and type 2 diabetes (70.7%). Notably, patients without NAFLD and MASLD exhibited a greater prevalence of advanced fibrosis (16.2% and 31.3% vs. 7.3% and 13.0%). Regression analysis identified type 2 diabetes as the strongest independent risk factor (OR ≈ 4), while NAFLD and MASLD criteria were inversely associated with fibrosis. Conclusion: The definition of MAFLD demonstrates a relatively good ability to identify patients with metabolic disorders and an increased risk of liver fibrosis, and also suggests that metabolic dysfunction may play an important role in the pathogenesis and progression of fatty liver disease.
Article Details
References
2. Tuong TTK, Tran DK, Phu PQT, Hong TND, Dinh TC, Chu DT (2020) Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan. Diagnostics (Basel Switzerland) 10(3). doi:10.3390/diagnostics10030159.
3. Eslam M, Fan JG, Yu ML et al (2025) The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatology international 19(2): 261-301. doi:10.1007/s12072-024-10774-3.
4. Vũ Quốc Bảo, Nguyễn Ngọc Tường Vy (2022) Tỷ lệ và một số đặc điểm bệnh gan nhiễm mỡ liên quan chuyển hóa ở bệnh nhân bị gan nhiễm mỡ tại Bệnh viện Nhân Dân Gia Định. Tạp chí y dược học Phạm Ngọc Thạch.
5. Portincasa P (2023) NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. Intern Emerg Med 18(4): 993-1006. doi:10.1007/s11739-023-03203-0.
6. Zamani M, Alizadeh-Tabari S, Ajmera V, Singh S, Murad MH, Loomba R (2025) Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 23(7): 1123-1134. doi:10.1016/j.cgh.2024.08.020.
7. Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md) 67(1):328-357. doi:10.1002/hep.29367.
8. Eslam M, Sanyal AJ, George J (2020) MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 158(7):1999-2014.e1. doi:10.1053/j.gastro.2019.11.312.
9. Rinella ME, Lazarus JV, Ratziu V et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology (Baltimore, Md) 78(6):1966-1986. doi:10.1097/hep.0000000000000520.
10. Yamamura S ea (2020) MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver International. 2020;(10.1111/liv.14675 12):40. doi:3018-3030.
11. van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ (2022) Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology 75(2): 419-429. doi:10.1002/hep.32131.
12. Huang X, Yu R, Tan X et al (2025) Comparison of NAFLD, MAFLD, and MASLD Prevalence and Clinical Characteristics in Asia Adults. J Clin Exp Hepatol 15(1): 102420. doi:10.1016/j.jceh.2024.102420.
13. Zou H, Ma X, Pan W, Xie Y (2024) Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population. Front Nutr 11: 1411802. doi:10.3389/fnut.2024.1411802.
14. Lin S, Huang J, Wang M et al (2020) Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 40(9):2082-2089. doi:10.1111/liv.14548.
15. Yamamura S, Eslam M, Kawaguchi T et al (2020) MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int 40(12):3018-3030. doi:10.1111/liv.14675.
16. Kuchay MS, Choudhary NS, Mishra SK (2020) Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr 14(6): 1875-1887. doi:10.1016/j.dsx.2020.09.026.
Article Sidebar
